Cervical cancer screening

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 12, Issue 3, 2014, Pages 333-341

  Partridge, Edward E ^a   Abu Rustum, Nadeem ^b   Giuliano, Anna ^c   Massad, Stewart ^d   McClure, Joan ^e   Dwyer, Mary ^e   Hughes, Miranda ^e  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d BARNES JEWISH HOSPITAL   (United States)

^e National Comprehensive Cancer Network   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RISK; CANCER SCREENING; CONSERVATIVE TREATMENT; CONTINUING EDUCATION; HUMAN; NON PROFIT ORGANIZATION; PRACTICE GUIDELINE; REVIEW; SCREENING TEST; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY;

EARLY DETECTION OF CANCER; FEMALE; HUMANS; UTERINE CERVICAL NEOPLASMS;

EID: 84897392873     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0035     Document Type: Review

References (40)

1. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012;137:516-542.
2. Moyer VA. Screening for cervical cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2012;156:880-891.
3. Whitlock EP, Vesco KK, Eder M, et al. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:687-697, W214-215.
4. Andrae B, Andersson TM, Lambert PC, et al. Screening and cervical cancer cure: population based cohort study. BMJ 2012;344:e900.
5. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
6. Schiffman M, Solomon D. Cervical-cancer screening with human papillomavirus and cytologic cotesting. N Engl J Med 2013;369:2324-2331.
7. Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010;102:1478-1488.
8. Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010;59:626-629.
9. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56:1-24.
10. International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer 2007;120:885-891.
11. Rodriguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010;102:315-324.
12. Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008;100:513-517.
13. Plummer M, Schiffman M, Castle PE, et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007;195:1582-1589. (Pubitemid 46799215)
14. ACOG Practice Bulletin no. 109: Cervical cytology screening. Obstet Gynecol 2009;114:1409-1420.
15. Meyerson BE, Crosby RA, Van Der Pol BJ, Zimet GD. Thinking differently about cervical cancer screening in highrisk populations. Am J Prev Med 2012;43:221-224.
16. Leyden WA, Manos MM, Geiger AM, et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst 2005;97:675-683. (Pubitemid 40812631)
17. Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2013;17:S1-27.
18. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011;12:663-672.
19. Ortoft G, Henriksen T, Hansen E, Petersen L. After conisation of the cervix, the perinatal mortality as a result of preterm delivery increases in subsequent pregnancy. BJOG 2010;117:258-267.
20. Castanon A, Brocklehurst P, Evans H, et al. Risk of preterm birth after treatment for cervical intraepithelial neoplasia among women attending colposcopy in England: retrospective-prospective cohort study. BMJ 2012;345:e5174.
21. Vesco KK, Whitlock EP, Eder M, et al. Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:698-705, W216.
22. Moscicki AB, Cox JT. Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. J Low Genit Tract Dis 2010;14:73-80.
23. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006;367:489-498. (Pubitemid 43208905)
24. Bruinsma FJ, Quinn MA. The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis. BJOG 2011;118:1031-1041.
25. Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008;337:a1284.
26. Wright TC, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007;197:346-355. (Pubitemid 47464164)
27. Moscicki AB, Shiboski S, Hills NK, et al. Regression of lowgrade squamous intra-epithelial lesions in young women. Lancet 2004;364:1678-1683. (Pubitemid 39458143)
28. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005;191:731-738. (Pubitemid 40271061)
29. Wright JD, Davila RM, Pinto KR, et al. Cervical dysplasia in adolescents. Obstet Gynecol 2005;106:115-120. (Pubitemid 40898442)
30. Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218-226. (Pubitemid 36152435)
31. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005;191:182-192. (Pubitemid 40096375)
32. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002;288:1749-1757.
33. Winer RL, Hughes JP, Feng Q, et al. Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev 2011;20:699-707.
34. Holowaty P, Miller AB, Rohan T, To T. RESPONSE: re: natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999;91:1420A-1421.
35. Chen HC, Schiffman M, Lin CY, et al. Persistence of type-specific human papillomavirus infection and increased longterm risk of cervical cancer. J Natl Cancer Inst 2011;103:1387-1396.
36. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-2119. (Pubitemid 34437346)
37. Solomon D, Stoler M, Jeronimo J, et al. Diagnostic utility of endocervical curettage in women undergoing colposcopy for equivocal or low-grade cytologic abnormalities. Obstet Gynecol 2007;110:288-295. (Pubitemid 47356652)
38. Massad LS, Collins YC. Using history and colposcopy to select women for endocervical curettage. Results from 2,287 cases. J Reprod Med 2003;48:1-6. (Pubitemid 36126033)
39. ACOG Practice Bulletin number 131: screening for cervical cancer. Obstet Gynecol 2012;120:1222-1238.
40. Darragh TM, Colgan TJ, Cox JT, et al. The Lower Angogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis 2012;16:205242. Erratum in J Low Genit Tract Dis 2013;17:368.